PepGen Inc. (PEPG)
| Market Cap | 105.83M +115.6% |
| Revenue (ttm) | n/a |
| Net Income | -77.22M |
| EPS | -1.51 |
| Shares Out | 69.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 501,576 |
| Open | 1.520 |
| Previous Close | 1.510 |
| Day's Range | 1.451 - 1.560 |
| 52-Week Range | 1.010 - 7.800 |
| Beta | 2.01 |
| Analysts | Strong Buy |
| Price Target | 10.14 (+562.75%) |
| Earnings Date | May 12, 2026 |
About PEPG
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Bo... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PEPG stock is "Strong Buy." The 12-month stock price target is $10.14, which is an increase of 562.75% from the latest price.
News
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen files $400M mixed securities shelf
12:08 EDT PepGen (PEPG) files $400M mixed securities shelf
PepGen Registration statement: Registration filing
PepGen filed a registration statement on May 18, 2026, providing details about a securities offering with the SEC.
PepGen price target lowered to $4 from $5 at Wedbush
Wedbush analyst Laura Chico lowered the firm’s price target on PepGen (PEPG) to $4 from $5 and keeps an Outperform rating on the shares. Most important in the Q1 update…
PepGen reports Q1 EPS (26c), consensus (31c)
“We made encouraging progress during the first quarter of 2026 in our FREEDOM2-DM1 trial. The 5 mg/kg cohort – the initial dose cohort – demonstrated a favorable tolerability profile and…
PepGen sees cash runway into 2H27
Cash, Cash Equivalents and Marketable Securities were $132.3 million as of March 31, 2026. Based on currently planned operations, the Company believes that its existing cash, cash equivalents, and mar...
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Quarterly report: Q1 2026
PepGen has published its Q1 2026 quarterly earnings report on May 12, 2026.
PepGen Earnings release: Q1 2026
PepGen released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
PepGen Slides: Company presentation
PepGen has posted slides in relation to its latest quarterly earnings report, which was published on May 12, 2026.
PepGen Proxy statement: Proxy filing
PepGen filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
PepGen Proxy statement: Proxy filing
PepGen filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
PepGen Slides: Company presentation
PepGen has posted slides in relation to its latest quarterly earnings report, which was published on April 17, 2026.
PepGen Transcript: Study update
The phase II FREEDOM2 study's lowest dose cohort (5 mg/kg) showed a favorable safety profile and promising splicing and vHOT improvements, with one rare outlier affecting group averages. Dose escalation to 10 mg/kg is underway, with results expected in H2 2026.
PepGen Press release: Study update
PepGen issued a press release on March 31, 2026, disclosing material business information to investors.
PepGen Slides: Study update
PepGen has posted slides in relation to its latest quarterly earnings report, which was published on March 31, 2026.
PepGen Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of PepGen Inc. (NASDAQ: PEPG). The investigation focuses on whether PepGen o...
PepGen down 46% at $2.30 after Phase 2 Freedom trial data
17:50 EDT PepGen (PEPG) down 46% at $2.30 after Phase 2 Freedom trial data
PepGen reports ‘promising’ topline results from MAD cohort
PepGen (PEPG) announced promising clinical data from the 5 mg/kg multiple ascending dose cohort of the ongoing Phase 2 FREEDOM2-DM1 trial in patients with myotonic dystrophy type 1. The Company…
PepGen Inc trading halted, news pending
16:01 EDT PepGen (PEPG) Inc trading halted, news pending
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of se...
PepGen Transcript: Leerink Global Healthcare Conference 2026
Recent data show record splicing improvements in DM1 patients, with ongoing multi-dose studies progressing internationally. Regulatory discussions with the FDA are focused on preclinical findings, while safety and efficacy data continue to support dose escalation and future phase III planning.
US FDA puts partial clinical hold on PepGen's muscle disease drug trial
PepGen said on Wednesday that the U.S. Food and Drug Administration has placed a partial clinical hold on its mid‑stage trial of a rare muscle disease drug, sending its shares plunging over 25% in e...